Jennifer Champoux Sells 2,175 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) COO Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the completion of the transaction, the chief operating officer directly owned 62,371 shares in the company, valued at approximately $1,247,420. The trade was a 3.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Monte Rosa Therapeutics Stock Up 1.7%

NASDAQ GLUE opened at $19.71 on Friday. Monte Rosa Therapeutics, Inc. has a 12-month low of $3.90 and a 12-month high of $25.77. The company has a market capitalization of $1.67 billion, a PE ratio of -13.32 and a beta of 1.62. The firm’s 50 day moving average is $18.20 and its 200-day moving average is $18.17.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The business had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. As a group, sell-side analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in GLUE. State Street Corp grew its stake in shares of Monte Rosa Therapeutics by 148.9% in the fourth quarter. State Street Corp now owns 2,107,480 shares of the company’s stock valued at $33,045,000 after buying an additional 1,260,707 shares in the last quarter. MPM Bioimpact LLC bought a new position in shares of Monte Rosa Therapeutics in the fourth quarter valued at $18,399,000. AQR Capital Management LLC grew its stake in shares of Monte Rosa Therapeutics by 459.4% in the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after buying an additional 1,054,406 shares in the last quarter. Braidwell LP bought a new position in shares of Monte Rosa Therapeutics in the fourth quarter valued at $14,870,000. Finally, Vestal Point Capital LP bought a new position in shares of Monte Rosa Therapeutics in the third quarter valued at $5,928,000. 79.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on GLUE. Wells Fargo & Company lowered their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. Guggenheim lowered their price objective on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Zacks Research downgraded shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 4th. Finally, Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $32.50.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.